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A decade ago, Mikhail Blagosklonny predicted that 
cellular senescence is driven by mitogenic pathways, 
when the cell cycle is blocked and actual growth is 
impossible [1]. In particular, the mitogen- and nutrient-
sensing mTOR (Target of Rapamycin) pathway drives 
either cell mass growth or aging [2]. Rapamycin 
prevents conversion of reversible cell cycle arrest to 
senescence [3-11]. When the cell cycle is blocked, but 
mTOR is still active, then cells become senescent. This 
process was named gerogenic conversion or simply 
geroconversion [12]. Rapamycin did not by-pass arrest 
but suppress geroconversion. Cells remained resting but 
not senescent.  The discovery of mTOR-dependent 
geroconversion allowed Blagosklonny to connect 
cellular aging to age-related diseases and organismal 
aging [13, 14]. Furthermore, this predicted that 
rapamycin is a gerosuppressant, which could be used to 
prevent age-related diseases by slowing down the aging 
process [14]. Independently, it was discovered that 
rapamycin suppresses chronological aging of yeast cells 
[15]. Chronological lifespan of yeast cells in stationary 
culture is the most fruitful model in aging research and 
dozens of papers have been published in Nature, 
Science, Cell and Cell Cycle. Although yeast model was 
so useful to identify genes involved in mammalian 
aging, the reason remained unclear. Yeast only loosely 
resemble post-mitotic cells in human tissues. 
Unfortunately, there was no model of mammalian 
chronological aging in cell culture. In one model 
developed by Fabrizio and Valter Longo [16] as well as 
by Matt Kaeberlein and Brian K. Kennedy [17], yeast 
chronological senescence (CS) is caused by acidosis 
due to overproduction of acetic acid. Obviously, neither 
replicative nor accelerated senescence of human cells 
resembles yeast CS in the stationary culture. 
Surprisingly, the exact replica was so well known and 
so trivial that it was overlooked by decades. Here 
Leontieva and Blagosklonny describe the mammalian 
cellular model: a neglected flask with overgrown cancer 
cells that turn medium “yellow” (due to lactate 
accumulation). Such flasks left and forgotten over 
weekend could be found in any CO2-incubator. The 
paper is simultaneously startling and obvious.  It is 
obvious from an everyday experience that highly glycol- 
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lytic cells can destroy cell culture. But like it was 
known to most researches (90 years ago) that fungi can 
destroy bacterial culture, it took a special insight to 
recognize the potential of this seemingly useless 
phenomenon.  There is an intriguing parallel between 
penicillin and rapamycin. As described in this issue of 
Aging, mTOR pathway is involved in glycolytic 
phenotype, causing self-poisoning due to over-
production of lactic acid. By decreasing lactate 
production, rapamycin prevents chronological 
senescence (CS). CS can be manipulated genetically 
and pharmacologically. Most importantly, the same 
agents that suppress geroconversion, organismal aging 
and cancer also suppress CS. 
 
This study does not break any dogma because there was 
no dogma as the field did not exist.   This paper opens a 
new filed in both aging and cancer research. 
Blagosklonny and collaborators are currently preparing 
follow-up papers with special emphasis to cancer 
research: the ability of rapamycin to decrease lactate 
production independently of respiration, selection of 
highly glycolytic cancer cell clones, tumor progression 
and resistance to therapy. Many questions will be 
answered. But this first paper defines the field, 
providing description of the phenomenon, its 
mechanism and the ways of pharmacological 
manipulation. It illuminates the place of yeast CS in 
aging research and its indirect (via common signaling 
pathways) relevance to cancer and organismal aging. It 
also rules out altruistic (programmed) aging of yeast 
because no one would suspect altruistic nature of cancer 
cells. I invite the readers to enjoy this first paper in the 
filed of mammalian cell chronological senescence.  
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